首頁 > 市場調查報告書 > 醫療設備

導管

經動脈化療栓塞術 (TACE) 市場規模、佔有率和成長分析（按手術類型、產品類型、適應症、最終用戶和地區分類）—2026-2033 年產業預測

市場調查報告書

商品編碼

1897279

經動脈化療栓塞術 (TACE) 市場規模、佔有率和成長分析（按手術類型、產品類型、適應症、最終用戶和地區分類）—2026-2033 年產業預測

Transarterial Chemoembolization Market Size, Share, and Growth Analysis, By Procedure Type, By Product Type, By Indication, By End-User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月26日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，經動脈化療栓塞術 (TACE) 市場規模將達到 106.6 億美元，到 2025 年將達到 111.4 億美元，到 2033 年將達到 158.4 億美元，在預測期（2026-2033 年）內複合年成長率為 4.5%。

全球經動脈化療栓塞術（TACE）市場正經歷顯著的變革時期，其主要驅動力是消費者對肝細胞癌（HCC）微創治療需求的不斷成長。隨著肝炎感染、飲酒和非酒精性脂肪肝（NFLD）等因素導致全球肝癌發生率上升，TACE市場預計將持續成長。醫療技術的進步，包括影像學、栓塞劑和藥物傳輸系統的創新，提高了TACE手術的精準度和效率，增強了其吸引力。人們對肝癌症狀的認知不斷提高，促使更多患者尋求早期診斷和治療方案，從而推動了TACE在中度肝癌治療中的應用。醫療基礎設施和法規結構的區域差異，尤其是在亞太等高發病率地區，持續影響市場動態。

經動脈化療栓塞術市場促進因素

全球肝癌發生率的不斷上升是經動脈化療栓塞術（TACE）市場發展的主要促進因素，因為它推動了對有效治療方法的需求。醫療技術的進步不斷提高這些手術的精準性和有效性，使其對醫護人員和患者都更具吸引力。此外，微創治療的趨勢也是推動TACE發展的關鍵因素，因為與傳統治療方法相比，這些方法通常能減輕患者的不適感。因此，由於疼痛減輕和恢復時間縮短，患者更傾向於選擇TACE。

限制經動脈化療栓塞市場發展的因素

經動脈化療栓塞術（TACE）市場面臨許多挑戰，主要原因在於肝癌患者的異質性及其複雜的治療反應，導致標準化治療難以實現。這種固有的複雜性要求個別化的治療方案，從而限制了TACE的廣泛應用。此外，嚴格的核准和報銷監管要求也構成了額外的障礙。報銷政策的差異和冗長的監管流程可能會阻礙TACE成為主流治療手段並融入標準醫療實踐。因此，這些因素不僅限制了TACE的普及，也限制了其在肝癌治療領域廣泛應用的潛力。

經動脈化療栓塞術（TACE）市場趨勢

經動脈化療栓塞術（TACE）市場正經歷著向個人化醫療的重大轉變，強調根據患者個別特徵和腫瘤情況制定針對肝癌的客製化治療方案。這種個人化治療不僅改善了治療效果，也契合了腫瘤學領域精準醫療的整體趨勢。同時，隨著研究不斷提高TACE手術的準確性和有效性，市場正經歷技術創新的蓬勃發展。栓塞劑、藥物釋放型微球技術和診斷影像技術的進步，使得更精準的治療性介入成為可能，從而減少對健康組織的損傷，並改善患者的整體預後。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Meril Life Sciences（India）
MicroPort（China）
Terumo Corporation（Japan）
Ethicon（Johnson & Johnson）（United States）
Neusoft Medical Systems Co., Ltd.（China）
Merit Medical Systems, Inc.（United States）
Guerbet Group（France）
AngioDynamics, Inc.（United States）
Boston Scientific（United States）
Medtronic（Ireland）
Beckton Dickinson（United States）
Cook Group（United States）
HealthTronics（United States）
IceCure Medical（Israel）
Profound Medical（Canada）
Siemens Healthineers（Germany）
GE Healthcare（United States）
Philips Healthcare（Netherlands）
Sirtex Medical（Australia）
BTG plc（United Kingdom）

結論與建議

簡介目錄

Product Code: SQMIG35I2318

Transarterial Chemoembolization Market size was valued at USD 10.66 Billion in 2024 and is poised to grow from USD 11.14 Billion in 2025 to USD 15.84 Billion by 2033, growing at a CAGR of 4.5% during the forecast period (2026-2033).

The global transarterial chemoembolization (TACE) market is experiencing a significant shift driven by rising consumer demand for minimally invasive treatments for hepatoma. As the global prevalence of liver cancer rises due to factors such as hepatitis infections, alcohol use, and non-alcoholic fatty liver disease, the market for TACE is poised for growth. Advancements in medical technology have enhanced the precision and efficiency of TACE procedures, with innovations in imaging, embolic agents, and drug delivery systems contributing to its attractiveness. Increased awareness of liver cancer symptoms has led more patients to pursue early diagnosis and treatment options, propelling the utilization of TACE for intermediate-grade liver cancer. Regional disparities in healthcare infrastructure and regulatory frameworks continue to shape market dynamics, particularly in high-incidence areas like Asia-Pacific.

Top-down and bottom-up approaches were used to estimate and validate the size of the Transarterial Chemoembolization market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Transarterial Chemoembolization Market Segments Analysis

Global Transarterial Chemoembolization Market is segmented by Procedure Type, Product Type, Indication, End-User and region. Based on Procedure Type, the market is segmented into Conventional TACE and DEB-TACE. Based on Product Type, the market is segmented into Chemotherapeutic Agents, Radiotherapeutic Agents and Drug-eluting Particles. Based on Indication, the market is segmented into Unresectable HCC and Early-Stage HCC. Based on End-User, the market is segmented into Hospitals and Clinics and Cancer Research Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Transarterial Chemoembolization Market

The growing global prevalence of liver cancer is a significant driver for the Transarterial Chemoembolization (TACE) market, as there is an increasing demand for effective treatment options. Advancements in medical techniques are continually enhancing the precision and effectiveness of these procedures, making them more appealing to both healthcare professionals and patients. Additionally, the trend towards minimally invasive treatments serves as a crucial factor in promoting TACE, as these methods typically result in less discomfort compared to conventional treatment approaches. Consequently, patients are more likely to favor TACE due to its reduced pain and recovery times.

Restraints in the Transarterial Chemoembolization Market

The Transarterial Chemoembolization market faces significant challenges primarily due to the varied nature of liver cancer patients and their complex treatment responses, which complicate standardization. This inherent complexity necessitates personalized treatment approaches, limiting TACE's broad application. Additionally, stringent regulatory requirements for approving and reimbursing medical procedures present further obstacles. Variations in reimbursement practices and lengthy regulatory processes can hinder the mainstream integration of TACE into standard healthcare practices. Consequently, these factors collectively restrict not only the adoption of TACE but also its potential to be widely utilized in the treatment landscape for liver cancer.

Market Trends of the Transarterial Chemoembolization Market

The Transarterial Chemoembolization (TACE) market is witnessing a significant shift towards personalized medicine, emphasizing tailored treatment approaches for liver cancer based on individual patient characteristics and tumor profiles. This customization enhances therapeutic outcomes and aligns with the broader movement towards precision medicine in oncology. Concurrently, the market is experiencing a surge in technological innovations, with ongoing research focused on enhancing the precision and efficacy of TACE procedures. Advances in embolic agents, drug-eluting bead technologies, and imaging capabilities are enabling more targeted therapeutic interventions, reducing collateral damage to healthy tissues and improving overall treatment effectiveness for patients.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement

Global Transarterial Chemoembolization Market Size by Procedure Type & CAGR (2026-2033)

Market Overview
Conventional TACE
DEB-TACE

Global Transarterial Chemoembolization Market Size by Product Type & CAGR (2026-2033)

Market Overview
Chemotherapeutic Agents
Radiotherapeutic Agents
Drug-eluting Particles

Global Transarterial Chemoembolization Market Size by Indication & CAGR (2026-2033)

Market Overview
Unresectable HCC
Early-Stage HCC

Global Transarterial Chemoembolization Market Size by End-User & CAGR (2026-2033)

Market Overview
Hospitals and Clinics
Cancer Research Centers

Global Transarterial Chemoembolization Market Size & CAGR (2026-2033)

North America (Procedure Type, Product Type, Indication, End-User)
- US
- Canada
Europe (Procedure Type, Product Type, Indication, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Procedure Type, Product Type, Indication, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Procedure Type, Product Type, Indication, End-User)
- Brazil
- Rest of Latin America
Middle East & Africa (Procedure Type, Product Type, Indication, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Meril Life Sciences (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MicroPort (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Terumo Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ethicon (Johnson & Johnson) (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neusoft Medical Systems Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merit Medical Systems, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guerbet Group (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AngioDynamics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boston Scientific (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beckton Dickinson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cook Group (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
HealthTronics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IceCure Medical (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Profound Medical (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Philips Healthcare (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sirtex Medical (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BTG plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments